Results 51 to 60 of about 1,569,619 (249)

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson   +20 more
wiley   +1 more source

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane   +11 more
wiley   +1 more source

Incidence and distribution of jaw pathologies among 0–15 years age group at a tertiary rural health-care center of Maharashtra: A retrospective study of 10 years

open access: yesContemporary Clinical Dentistry, 2020
Objective: This study was undertaken to investigate the prevalence of intraosseous jaw lesions among pediatrics (0–15 years of age) in a rural health-care center of Maharashtra and to determine the most common types of lesions and their distribution ...
Parul Tandon   +4 more
doaj   +1 more source

Implementing Health‐Related Quality of Life Assessment in Pediatric Oncology: A Feasibility Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background There is growing interest in embedding health‐related quality of life (HRQoL) assessment and patient‐reported outcome measures (PROMs) within clinical cancer care. This study evaluated the feasibility, acceptability, and usability of implementing an electronic PROM (ePROM) platform to measure HRQoL in children with cancer ...
Mikaela Doig   +13 more
wiley   +1 more source

Prediction of bladder tumor relapse based on the risk factors and characteristics of the treatment [PDF]

open access: yesMedičnì Perspektivi, 2015
Objectives. To investigate the possibility of predicting recurrence of bladder tumors based on the clinical and morphological features of the disease and preoperative intravesical instillation of probiotic Aerococcus viridans 167.
Molchanov R.N., Blyuss O.B.
doaj  

[Infratentorial tumors].

open access: yesDer Radiologe, 2007
This article gives an overview concerning the typical infratentorial tumors of adults.
Grunwald, I   +5 more
openaire   +3 more sources

Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents.
Amanda M. Gutierrez   +14 more
wiley   +1 more source

Fecal Microbiota Transplantation in Refractory Immune-Mediated Colitis: Case Series and Review of the Literature

open access: yesPharmaceuticals
Background/Objectives: Immune checkpoint inhibitors (ICI) represent a significant breakthrough in cancer management, but they can cause adverse effects such as immune-mediated colitis (IMC).
Marin Golčić   +16 more
doaj   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano   +7 more
wiley   +1 more source

[Cardiac tumors].

open access: yesPathologica, 2005
Primary cardiac tumors are rare and their subdivision often difficult because of their unknown origin. In the most recent classification, cardiac tumors are divided into benign (about 75% and malignant neoplasms in relationship to their tissue differentiation (rhabdomyoma, haemangioma, etc.) or uncertain aetiology (myxoma, papillary fibroelastoma ...
ORLANDI, AUGUSTO   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy